DOCSLIB.ORG

NOTICE: in July 2004, the Training Program Director's Core

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NOTICE: in July 2004, the Training Program Director's Core Core Curriculum Outline and Reading List Last Reviewed:May 2011 The Allergy and Immunology Training Program Directors’ (TPD) Core Curriculum Outline and Reading List serves as a guide for: TPD and trainees in meeting the requirements of the Residency Review Committee The Reading List Subcommittee The In-Training Examination Subcommittee. This document provides a framework for training programs to design an individualized course of study that supplements the diverse strengths and weaknesses of each fellowship training program and faculty. It is updated every three years, and is consistent with the requirements of the Residency review Committee for training in allergy and immunology. In an effort to keep the materials as current as possible, email Mariana Duran at [email protected] with supplemental inforamtion. Suggestions will be reviewed at the end of each calendar year. Allergy and Immunology Training Program Directors’ Core Curriculum Outline and Reading List Click on any of the Core Curriculum topics to view the citation and abstract of the reading(s) or activities selected for each Core Curriculum topic. Strategies and resources for acquiring the body of knowledge within the Basic Science Core Curriculum might include structured didactic programs, TPD-recommended textbooks, TPD reading list, and regional or national seminars. The knowledge obtained through the basic science curriculum serves as the foundation for diagnosis and therapy for immunologic and allergic disorders. 1 I. Basic Immunology........................................................................................................................ 10 A. Overview of the Immune System ........................................................................................... 10 1. Organization and Functions of the Immune System............................................................ 10 a. Thymic development and shaping peripheral systemic T-cell immunity ........................ 10 b. Cutaneous Immunity........................................................................................................ 11 c. Intestinal/Mucosal Immunity ........................................................................................... 11 d. Primary Immune Function of Cellular Elements of the Immune System........................ 12 i. T-cells ........................................................................................................................... 12 ii. B cells .......................................................................................................................... 13 iii. Neutrophils ................................................................................................................. 14 iv. Eosinophils.................................................................................................................. 15 v. Mast cells ..................................................................................................................... 15 vi. Basophils..................................................................................................................... 16 vii. Antigen presenting cells ............................................................................................ 17 viii. Natural Killer Cells................................................................................................... 18 ix. NKT cells.................................................................................................................... 19 x. Platelets........................................................................................................................ 19 xi. Epithelium................................................................................................................... 20 B. Immune Mechanisms .............................................................................................................. 20 1. Innate versus adaptive immunity ......................................................................................... 20 a. Complement and the innate immune response................................................................. 21 b. Pattern Recognition Receptors......................................................................................... 23 c. Natural Antimicrobial Agents.......................................................................................... 25 i. reactive oxygen species ................................................................................................ 25 ii. releasable granule proteins .......................................................................................... 25 2. Major histocompatibility complex – molecular structure and function............................... 26 3. Immunogenetics – Gene rearrangements in the generation of immune system diversity ... 27 4. Antigen-presenting cells – processing and presentation of conventional and superantigens .................................................................................................................................................. 28 5. Gell and Coombs Classification of Immune Responses...................................................... 29 a. Type I –Immediate Hypersensitivity Response ............................................................... 30 i. IgE binding and signal transduction ............................................................................. 30 ii preformed and newly synthesized mediator release ..................................................... 31 iii late phase reactions...................................................................................................... 32 b. Type II – Antibody induced reactions Response ............................................................. 32 c. Type III – Immune-Complex mediated reactions ............................................................ 32 d. Type IV – Cell mediated /Delayed Hypersensitivity Response....................................... 33 6. T cell mediated immunity .................................................................................................... 34 a. T cell activation – T cell receptor structure and function, epitope recognition and accessory molecules in signal transduction ......................................................................... 34 b. Cytokines and co-stimulatory molecules in T cell activation.......................................... 35 c. T cell mediated immune responses – participating cells. Properties and functions of antigen presenting cells........................................................................................................36 d. T cell subsets.................................................................................................................... 39 e. Regulatory T cells and Memory T Cells.......................................................................... 41 f. NK T cells......................................................................................................................... 44 2 7. B cell mediated immunity.................................................................................................... 45 a. B cell activation – cytokines and signal transduction ...................................................... 46 b. Epitope recognition and immunoglobulin production ..................................................... 48 c. Maturation of B lymphocytes........................................................................................... 49 d. Maturation of the antibody response................................................................................ 51 e. Biologic process initiated by antibody: opsonization, complement fixation, antibody dependent cell mediated cytotoxicity................................................................................... 52 f. IgE mediated immediate and late phase reactions........................................................... 54 g. Immune complexes – immunologic properties and mechanisms of clearance................ 55 8. Other immune and inflammatory mechanisms.................................................................... 56 a. Natural killer cells, their CD markers and functions........................................................ 56 b. Lymphokine activated killer cells and their effects ......................................................... 57 c. Basophil mediated inflammatory states ........................................................................... 58 d. Kinin mediated inflammation .......................................................................................... 60 e. Arachidonic acid metabolites inflammation .................................................................... 61 f. Cytokines/chemokines and their receptors....................................................................... 63 g. Growth factors ................................................................................................................ 65 9. Receptor Ligand interactions in immune functioning—signal transduction resulting from receptor ligand interaction - genetic polymorphisms............................................................... 65 10. Immunologic Memory ....................................................................................................... 69 C. Mucosal Immunity .................................................................................................................. 73 1. Adaptive Immunity .............................................................................................................
Load more

Recommended publications
  • Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections
    Review Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections 1,2, , 3, 4 3 Bapi Pahar * y , Stefania Madonna y , Arpita Das , Cristina Albanesi and Giampiero Girolomoni 5 1 Division of Comparative Pathology, Tulane National Primate Research Center, Covington, LA 70433, USA 2 Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70118, USA 3 IDI-IRCCS, Dermopathic Institute of the Immaculate IDI, 00167 Rome, Italy; [email protected] (S.M.); [email protected] (C.A.) 4 Division of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA; [email protected] 5 Section of Dermatology, Department of Medicine, University of Verona, 37126 Verona, Italy; [email protected] * Correspondence: [email protected] Authors contributed equally. y Received: 4 August 2020; Accepted: 7 September 2020; Published: 10 September 2020 Abstract: Antimicrobial peptides (AMPs) are produced by neutrophils, monocytes, and macrophages, as well as epithelial cells, and are an essential component of innate immunity system against infection, including several viral infections. AMPs, in particular the cathelicidin LL-37, also exert numerous immunomodulatory activities by inducing cytokine production and attracting and regulating the activity of immune cells. AMPs are scarcely expressed in normal skin, but their expression increases when skin is injured by external factors, such as trauma, inflammation, or infection. LL-37 complexed to self-DNA acts as autoantigen in psoriasis and lupus erythematosus (LE), where it also induces production of interferon by plasmocytoid dendritic cells and thus initiates a cascade of autocrine and paracrine processes, leading to a disease state.
    [Show full text]
  • The Avian Heterophil ⇑ Kenneth J
    Developmental and Comparative Immunology xxx (2013) xxx–xxx Contents lists available at SciVerse ScienceDirect Developmental and Comparative Immunology journal homepage: www.elsevier.com/locate/dci The avian heterophil ⇑ Kenneth J. Genovese ,1, Haiqi He 1, Christina L. Swaggerty 1, Michael H. Kogut U.S. Department of Agriculture, Agricultural Research Service, Food and Feed Safety Research Unit, College Station, TX 77845, USA article info abstract Article history: Heterophils play an indispensable role in the immune defense of the avian host. To accomplish this Available online xxxx defense, heterophils use sophisticated mechanisms to both detect and destroy pathogenic microbes. Detection of pathogens through the toll-like receptors (TLR), FC and complement receptors, and other Keywords: pathogen recognition receptors has been recently described for the avian heterophil. Upon detection of Heterophil pathogens, the avian heterophil, through a network of intracellular signaling pathways and the release Innate immunity and response to cytokines and chemokines, responds using a repertoire of microbial killing mechanisms Avian including production of an oxidative burst, cellular degranulation, and production of extracellular matri- Poultry ces of DNA and histones (HETs). In this review, the authors describe the recent advances in our under- Granulocyte standing of the avian heterophil, its functions, receptors and signaling, identified antimicrobial products, cytokine and chemokine production, and some of the effects of genetic selection on heterophils and their functional characteristics. Published by Elsevier Ltd. 1. Introduction including its functions, receptors, intracellular signaling, antimi- crobial products, and the known genetics related to its functional Avian species, specifically domestic poultry, are constantly ex- efficiency. posed to a myriad of pathogens and microbes in their environ- ments.
    [Show full text]
  • Advances in Immunosuppression for Renal Transplantation Antoine Durrbach, Helene Francois, Severine Beaudreuil, Antoine Jacquet and Bernard Charpentier
    REVIEWS Advances in immunosuppression for renal transplantation Antoine Durrbach, Helene Francois, Severine Beaudreuil, Antoine Jacquet and Bernard Charpentier Abstract | The development of immunosuppressants with minimal adverse and nephrotoxic effects is important to improve outcomes, such as acute and chronic antibody-mediated rejection, after organ transplantation. In addition, the application of expanded criteria for donors and transplantation in immunized patients necessitates the development of new therapies. Drug development over the past 10 years has generally been disappointing, but several new promising compounds have been or are being developed to prevent acute and chronic transplant rejection. In this Review, we report on several compounds that have been developed to remove allogenic T cells and/or to inhibit T-cell activation. We also discuss compounds that interfere with antibody-mediated rejection. Durrbach, A. et al. Nat. Rev. Nephrol. 6, 160–167 (2010); published online 2 February 2010; doi:10.1038/nrneph.2009.233 Introduction Renal transplantation has specific features that make or as a result of previous transplantation, has increased it different from transplantation procedures for other over the past decade. In addition, ABO­incompatible organs. For example, outcomes can be affected by grafts are becoming more frequently used. Together, these common states, such as donor and/or recipient age, high factors have led to a rise in the number of ‘immuno logically blood pressure, diabetes mellitus, metabolic disturbances at­risk’ kidney transplantations. Few immunosuppressants (such as high LDL cholesterol) and abnormalities in fluid targeted to B cells have, however, been available to control and electrolyte balance. The kidney is also very sensitive the antibody­mediated response.
    [Show full text]
  • Oral Tolerance: Therapeutic Implications for Autoimmune Diseases
    Clinical & Developmental Immunology, June–December 2006; 13(2–4): 143–157 Oral tolerance: Therapeutic implications for autoimmune diseases ANA M. C. FARIA1 & HOWARD L. WEINER2 1Departamento de Bioquı´mica e Imunologia, Instituto de Cieˆncias Biolo´gicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil, and 2Harvard Medical School, Center for Neurologic Diseases, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, Boston, MA 02115, USA Abstract Oral tolerance is classically defined as the suppression of immune responses to antigens (Ag) that have been administered previously by the oral route. Multiple mechanisms of tolerance are induced by oral Ag. Low doses favor active suppression, whereas higher doses favor clonal anergy/deletion. Oral Ag induces Th2 (IL-4/IL-10) and Th3 (TGF-b) regulatory T cells (Tregs) plus CD4þCD25þ regulatory cells and LAPþT cells. Induction of oral tolerance is enhanced by IL-4, IL-10, anti-IL-12, TGF-b, cholera toxin B subunit (CTB), Flt-3 ligand, anti-CD40 ligand and continuous feeding of Ag. In addition to oral tolerance, nasal tolerance has also been shown to be effective in suppressing inflammatory conditions with the advantage of a lower dose requirement. Oral and nasal tolerance suppress several animal models of autoimmune diseases including experimental allergic encephalomyelitis (EAE), uveitis, thyroiditis, myasthenia, arthritis and diabetes in the nonobese diabetic (NOD) mouse, plus non-autoimmune diseases such as asthma, atherosclerosis, colitis and stroke. Oral tolerance has been tested in human autoimmune diseases including MS, arthritis, uveitis and diabetes and in allergy, contact sensitivity to DNCB, nickel allergy.
    [Show full text]
  • Biologic Armamentarium in Psoriasis
    Vol 9, Issue 1, 2016 ISSN - 0974-2441 Review Article BIOLOGIC ARMAMENTARIUM IN PSORIASIS GANESH PAI1*, NITHIN SASHIDHARAN2 1Medical Director, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. 2Consultant Clinical Pharmacologist, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. Email: [email protected] Received: 14 July 2015, Revised and Accepted: 24 August 2015 ABSTRACT Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition serving as a global burden. A moderate to severe psoriasis can be treated with conventional therapies. Less efficacy, poor patient compliance, and toxicity issues were the major problems associated with conventional therapies. The introduction of biologic therapy has a great impression on psoriatic treatment duration and enhanced quality of life in psoriasis patients. The new biologic therapies are tailor-made medications with the goal of more specific and effective treatment; less toxicity. The biologic therapy is aimed to target antigen presentation and co-stimulation, T-cell activation, and leukocyte adhesion; and pro-inflammatory cascade. They act as effective and safer substitute to traditional therapy. Secukinumab, certolizumab, itolizumab, golimumab, ustekinumab, adalimumab, infliximab etanercept, alefacept, etc. are the approved biologic with the global market. This review briefs about psoriasis pathogenesis, traditional treatments, and biologic therapies potential. Keywords: Psoriasis, Biologic, Non-biologic treatment. INTRODUCTION migration, potentiation of Th1 type of response, angiogenesis, and epidermal hyperplasia [7]. Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition with prevalence ranging 1-3% in the TNF- is plays vital role in the pathogenesis of psoriasis. It acts by world [1].
    [Show full text]
  • Antimicrobial Activity of Cathelicidin Peptides and Defensin Against Oral Yeast and Bacteria JH Wong, TB Ng *, RCF Cheung, X Dan, YS Chan, M Hui
    RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Antimicrobial activity of cathelicidin peptides and defensin against oral yeast and bacteria JH Wong, TB Ng *, RCF Cheung, X Dan, YS Chan, M Hui KEY MESSAGES Mycosphaerella arachidicola, Saccharomyces cerevisiae and C albicans with an IC value of 1. Human cathelicidin LL37 and its fragments 50 3.9, 4.0, and 8.4 μM, respectively. The peptide LL13-37 and LL17-32 were equipotent in increased fungal membrane permeability. inhibiting growth of Candida albicans. 6. LL37 did not show obvious antibacterial activity 2. LL13-37 permeabilised the membrane of yeast below a concentration of 64 μM and its fragments and hyphal forms of C albicans and adversely did not show antibacterial activity below a affected mitochondria. concentration of 128 μM. Pole bean defensin 3. Reactive oxygen species was detectable in the exerted antibacterial activity on some bacterial yeast form after LL13-37 treatment but not in species. untreated cells suggesting that the increased membrane permeability caused by LL13-37 might also lead to uptake of the peptide, which Hong Kong Med J 2016;22(Suppl 7):S37-40 might have some intracellular targets. RFCID project number: 09080432 4. LL37 and its fragments also showed antifungal 1 JH Wong, 1 TB Ng, 1 RCF Cheung, 1 X Dan, 1 YS Chan, 2 M Hui activity against C krusei, and C tropicalis. 5. A 5447-Da antifungal peptide with sequence The Chinese University of Hong Kong: 1 School of Biomedical Sciences homology to plant defensins was purified from 2 Department of Microbiology king pole beans by chromatography on Q- Sepharose and FPLC-gel filtration on Superdex * Principal applicant and corresponding author: 75.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • The Distribution of Immune Cells in the Uveal Tract of the Normal Eye
    THE DISTRIBUTION OF IMMUNE CELLS IN THE UVEAL TRACT OF THE NORMAL EYE PAUL G. McMENAMIN Perth, Western Australia SUMMARY function of these cells in the normal iris, ciliary body Inflammatory and immune-mediated diseases of the and choroid. The role of such cell types in ocular eye are not purely the consequence of infiltrating inflammation, which will be discussed by other inflammatory cells but may be initiated or propagated authors in this issue, is not the major focus of this by immune cells which are resident or trafficking review; however, a few issues will be briefly through the normal eye. The uveal tract in particular considered where appropriate. is the major site of many such cells, including resident tissue macro phages, dendritic cells and mast cells. This MACRO PHAGES review considers the distribution and location of these and other cells in the iris, ciliary body and choroid in Mononuclear phagocytes arise from bone marrow the normal eye. The uveal tract contains rich networks precursors and after a brief journey in the blood as of both resident macrophages and MHe class 11+ monocytes immigrate into tissues to become macro­ dendritic cells. The latter appear strategically located to phages. In their mature form they are widely act as sentinels for capturing and sampling blood-borne distributed throughout the body. Macrophages are and intraocular antigens. Large numbers of mast cells professional phagocytes and play a pivotal role as are present in the choroid of most species but are effector cells in cell-mediated immunity and inflam­ virtually absent from the anterior uvea in many mation.1 In addition, due to their active secretion of a laboratory animals; however, the human iris does range of important biologically active molecules such contain mast cells.
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • Human Peptides -Defensin-1 and -5 Inhibit Pertussis Toxin
    toxins Article Human Peptides α-Defensin-1 and -5 Inhibit Pertussis Toxin Carolin Kling 1, Arto T. Pulliainen 2, Holger Barth 1 and Katharina Ernst 1,* 1 Institute of Pharmacology and Toxicology, Ulm University Medical Center, 89081 Ulm, Germany; [email protected] (C.K.); [email protected] (H.B.) 2 Institute of Biomedicine, Research Unit for Infection and Immunity, University of Turku, FI-20520 Turku, Finland; arto.pulliainen@utu.fi * Correspondence: [email protected] Abstract: Bordetella pertussis causes the severe childhood disease whooping cough, by releasing several toxins, including pertussis toxin (PT) as a major virulence factor. PT is an AB5-type toxin, and consists of the enzymatic A-subunit PTS1 and five B-subunits, which facilitate binding to cells and transport of PTS1 into the cytosol. PTS1 ADP-ribosylates α-subunits of inhibitory G-proteins (Gαi) in the cytosol, which leads to disturbed cAMP signaling. Since PT is crucial for causing severe courses of disease, our aim is to identify new inhibitors against PT, to provide starting points for novel therapeutic approaches. Here, we investigated the effect of human antimicrobial peptides of the defensin family on PT. We demonstrated that PTS1 enzyme activity in vitro was inhibited by α-defensin-1 and -5, but not β-defensin-1. The amount of ADP-ribosylated Gαi was significantly reduced in PT-treated cells, in the presence of α-defensin-1 and -5. Moreover, both α-defensins decreased PT-mediated effects on cAMP signaling in the living cell-based interference in the Gαi- mediated signal transduction (iGIST) assay.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew Et Al
    US 2016.0058872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew et al. (43) Pub. Date: Mar. 3, 2016 (54) IMIDE-BASED MODULATORS OF A613 L/426 (2006.01) PROTEOLYSIS AND ASSOCATED METHODS A 6LX3 L/505 (2006.01) OF USE A613 L/454 (2006.01) A613 L/55 (2006.01) (71) Applicant: Arvinas, Inc., New Haven, CT (US) C07D40 L/4 (2006.01) A6II 45/06 (2006.01) (72) Inventors: Andrew P. Crew, Guilford, CT (US); (52) U.S. Cl. Craig Crews, New Haven, CT (US), CPC ............ A61K 47/481 (2013.01); C07D401/14 Hanging Dong, Madison, CT (US); Jing (2013.01); C07D 495/14 (2013.01); C07D Wang, Milford, CT (US); Yimin Qian, 417/14 (2013.01); A61K 45/06 (2013.01); Plainsboro, NJ (US); Kam Siu Milford, A6 IK3I/505 (2013.01); A61 K3I/454 CT (US); Meizhong Jin, East Northport, (2013.01); A61 K3I/551 (2013.01); A61 K NY (US) 3 1/426 (2013.01) (21) Appl. No.: 14/792,414 (57) ABSTRACT (22) Filed: Jul. 6, 2015 The description relates to imide-based compounds, including Related U.S. Application Data bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially (63) Continuation-in-part of application No. 14/686.640, inhibitors of a variety of polypeptides and other proteins filed on Apr. 14, 2015. which are degraded and/or otherwise inhibited by bifunc (60) Provisional application No. 61/979,351, filed on Apr. tional compounds according to the present invention. In par 14, 2014, provisional application No.
    [Show full text]
  • Instant Notes: Immunology, Second Edition
    Immunology Second Edition The INSTANT NOTES series Series Editor: B.D. Hames School of Biochemistry and Molecular Biology, University of Leeds, Leeds, UK Animal Biology 2nd edition Biochemistry 2nd edition Bioinformatics Chemistry for Biologists 2nd edition Developmental Biology Ecology 2nd edition Immunology 2nd edition Genetics 2nd edition Microbiology 2nd edition Molecular Biology 2nd edition Neuroscience Plant Biology Chemistry series Consulting Editor: Howard Stanbury Analytical Chemistry Inorganic Chemistry 2nd edition Medicinal Chemistry Organic Chemistry 2nd edition Physical Chemistry Psychology series Sub-series Editor: Hugh Wagner Dept of Psychology, University of Central Lancashire, Preston, UK Psychology Cognitive Psychology Forthcoming title Physiological Psychology Immunology Second Edition P.M. Lydyard Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, University College London, London, UK A. Whelan Department of Immunology, Trinity College and St James’ Hospital, Dublin, Ireland and M.W. Fanger Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire, USA © Garland Science/BIOS Scientific Publishers Limited, 2004 First published 2000 This edition published in the Taylor & Francis e-Library, 2005. “To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk.” Second edition published 2004 All rights reserved. No part of this book may be reproduced or
    [Show full text]